65,437 trials
Non-Small Cell Lung Cancer
Primary: Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1 — 121; 77.5; 78.3 micrograms per milliliter (μg/mL)
Hernia, Ventral
Primary: Surgical Site Occurrences or Wound-related Events — 0; 10; 3; 4 Participants
Pelvic Pain · Chronic Pelvic Pain · Recurrent Pelvic Pain
Primary: Number of Randomized Participants Who: a) Are Retained at 8 Weeks, b) Attend at Least 75% of Intervention Classes, c) Demonstrate at Least Moderate Intervention…
Functional Gastrointestinal Disorders
Primary: Nausea Severity Scale — 2.18; 2.45 units on a scale
Disease;Neurological
Primary: Percent of Participants With Visible Region of Interest (Imaging Visibility) — 100 percentage of participants
Alzheimer Disease · Dementia of Alzheimer Type
Primary: Event-related Potential (ERP) P300 Latency at Baseline — 361.5; 382.3; 375.3 Milliseconds (ms)
Amyotrophic Lateral Sclerosis
Primary: Disease Progression as Assessed by the ALSFRS-R-Slope — -1.02; -1.05 ALSFRS-R total score points per month
HIV
Primary: Change in Arterial Target to Background Ratio of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Uptake — -0.28; 0.01 ratio — p=0.01
Acute Ischemic Stroke · Transient Ischemic Attack (TIA)
Primary: Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by…
HER2-Positive Breast Carcinoma · Hormone Receptor-Positive Breast Carcinoma · Stage IB Breast Cancer AJCC v7
Primary: Percent of Patients With Pathological Complete Response (pCR) in the Breast and Post Therapy Lymph Nodes — 41.2; 45.8 percentage of participants
Obesity
Primary: Neuronal Response to Visual Food Cues — .035; .045; .029; .019 % BOLD signal — p=0.647
Respiratory Disease · Pulmonary Disease · Pediatric ALL
Primary: Proximal Pressure From Trilogy Evo Ventilator and Current Device — 8.3; 8.2 cm H2O
Preneoplastic Conditions · Prostatic Intraepithelial Neoplasia
Primary: Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN) — 54.9; 59.5 % of participants cancer-free…
Hearing Loss
Primary: Trial to Success Rate — 2; 0 Participants
Parkinson Disease
Primary: Change in Tele-visit Modified MDS-UPDRS Parts 1-3 (Total Score) — 2.197; 8.943 score on a scale — p=0.006